Long-term outcomes and prognosis of neuroendocrine neoplasms of the head and neck: a cohort from a single institution.
Neuroendocrine neoplasm of the head and neck
Radiotherapy
Survival outcome
Treatment regimens
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
05
03
2024
accepted:
25
03
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
Neuroendocrine neoplasm is a rare cancer of head and neck. This study aimed to evaluate clinical features, treatment outcomes, and prognostic factors of neuroendocrine neoplasm of head and neck treated at a single institution. Between Nov 2000 and Nov 2021, ninety-three patients diagnosed with neuroendocrine neoplasms of head and neck treated at our institution were reviewed retrospectively. The initial treatments included chemotherapy (induction, adjuvant, or concurrent) combined with radiotherapy in 40 patients (C + RT group), surgery followed by post-operative RT in 34 (S + RT group), and surgery plus salvage therapy in 19 patients (S + Sa group). The median follow-up time was 64.5 months. 5-year overall survival rate (OS), progression-free survival rate (PFS), loco-regional relapse-free survival free rate (LRRFS) and distant metastasis-free survival rate (DMFS) were 64.5%, 51.6%, 66.6%, and 62.1%, respectively. For stage I-II, the 5-year LRRFS for patients' treatment regimen with or without radiotherapy (C + RT and S + RT groups versus S + Sa group) was 75.0% versus 12.7% (p = 0.015) while for stage III-IV, the 5-year LRRFS was 77.8% versus 50.0% (p = 0.006). The 5-year DMFS values for patients with or without systemic therapy (C + RT group versus S + RT or S + Sa) were 71.2% and 51.5% (p = 0.075). 44 patients (47.3%) experienced treatment failure and distant metastasis was the main failure pattern. Radiotherapy improved local-regional control and played an important role in the management of HNNENs. The optimal treatment regimen for HNNENs remains the combination of local and systemic treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine neoplasm is a rare cancer of head and neck. This study aimed to evaluate clinical features, treatment outcomes, and prognostic factors of neuroendocrine neoplasm of head and neck treated at a single institution.
METHODS
METHODS
Between Nov 2000 and Nov 2021, ninety-three patients diagnosed with neuroendocrine neoplasms of head and neck treated at our institution were reviewed retrospectively. The initial treatments included chemotherapy (induction, adjuvant, or concurrent) combined with radiotherapy in 40 patients (C + RT group), surgery followed by post-operative RT in 34 (S + RT group), and surgery plus salvage therapy in 19 patients (S + Sa group).
RESULTS
RESULTS
The median follow-up time was 64.5 months. 5-year overall survival rate (OS), progression-free survival rate (PFS), loco-regional relapse-free survival free rate (LRRFS) and distant metastasis-free survival rate (DMFS) were 64.5%, 51.6%, 66.6%, and 62.1%, respectively. For stage I-II, the 5-year LRRFS for patients' treatment regimen with or without radiotherapy (C + RT and S + RT groups versus S + Sa group) was 75.0% versus 12.7% (p = 0.015) while for stage III-IV, the 5-year LRRFS was 77.8% versus 50.0% (p = 0.006). The 5-year DMFS values for patients with or without systemic therapy (C + RT group versus S + RT or S + Sa) were 71.2% and 51.5% (p = 0.075). 44 patients (47.3%) experienced treatment failure and distant metastasis was the main failure pattern.
CONCLUSIONS
CONCLUSIONS
Radiotherapy improved local-regional control and played an important role in the management of HNNENs. The optimal treatment regimen for HNNENs remains the combination of local and systemic treatments.
Identifiants
pubmed: 38834932
doi: 10.1007/s00432-024-05726-1
pii: 10.1007/s00432-024-05726-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
288Informations de copyright
© 2024. The Author(s).
Références
Bal M, Sharma A, Rane SU, Mittal N, Chaukar D, Prabhash K, Patil A (2022) Neuroendocrine neoplasms of the larynx: a clinicopathologic analysis of 27 neuroendocrine tumors and neuroendocrine carcinomas. Head Neck Pathol 16(2):375–387. https://doi.org/10.1007/s12105-021-01367-9
doi: 10.1007/s12105-021-01367-9
pubmed: 34401980
Ferlito A, Devaney KO, Rinaldo A (2006) Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. Oral Oncol 42(8):770–788. https://doi.org/10.1016/j.oraloncology.2006.01.002
doi: 10.1016/j.oraloncology.2006.01.002
pubmed: 16815077
Ghosh R, Dutta R, Dubal PM, Park RC, Baredes S, Eloy JA (2015) Laryngeal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Otolaryngol Head Neck Surg 153(6):966–972. https://doi.org/10.1177/0194599815594386
doi: 10.1177/0194599815594386
pubmed: 26183520
Issa K, Ackall F, Jung SH, Li J, Jang DW, Rangarajan SV, Abi Hachem R (2021) Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: a NCDB analysis. Am J Otolaryngol 42(2):102851. https://doi.org/10.1016/j.amjoto.2020.102851
doi: 10.1016/j.amjoto.2020.102851
pubmed: 33385873
Kao HL, Chang WC, Li WY, Chia-Heng Li A, Fen-Yau Li A (2012) Head and neck large cell neuroendocrine carcinoma should be separated from atypical carcinoid on the basis of different clinical features, overall survival, and pathogenesis. Am J Surg Pathol 36(2):185–192. https://doi.org/10.1097/PAS.0b013e318236d822
doi: 10.1097/PAS.0b013e318236d822
pubmed: 22082601
Kuan EC, Alonso JE, Tajudeen BA, Arshi A, Mallen-St Clair J, St John MA (2017) Small cell carcinoma of the head and neck: a comparative study by primary site based on population data. Laryngoscope 127(8):1785–1790. https://doi.org/10.1002/lary.26406
doi: 10.1002/lary.26406
pubmed: 27859290
Lin AJ, Gabani P, Fischer-Valuck B, Rudra S, Gay H, Daly M, Thorstad W (2019) Patterns of care and survival outcomes for laryngeal small cell cancer. Head Neck 41(3):722–729. https://doi.org/10.1002/hed.25430
doi: 10.1002/hed.25430
pubmed: 30785231
Matsuyama H, Ueki Y, Okamoto I, Nagao T, Honda K, Yamazaki K, Horii A (2022) Head and neck small-cell carcinoma: a multicenter study of 39 cases from 10 institutions. Front Surg 9:1049116. https://doi.org/10.3389/fsurg.2022.1049116
doi: 10.3389/fsurg.2022.1049116
pubmed: 36451679
pmcid: 9701733
Mete O, Wenig BM (2022) Update from the 5th edition of the World Health Organization Classification of head and neck tumors: overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol 16(1):123–142. https://doi.org/10.1007/s12105-022-01435-8
doi: 10.1007/s12105-022-01435-8
pubmed: 35312985
pmcid: 9018952
Mitchell MB, Kimura K, Chapurin N, Saab Chalhoub M, Mehrad M, Langerman A, Kim Y (2021) Neuroendocrine carcinomas of the head and neck: a small case series. Am J Otolaryngol 42(4):102992. https://doi.org/10.1016/j.amjoto.2021.102992
doi: 10.1016/j.amjoto.2021.102992
pubmed: 33640803
Ohmoto A, Sato Y, Asaka R, Fukuda N, Wang X, Urasaki T, Takahashi S (2021) Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. Mod Pathol 34(11):1979–1989. https://doi.org/10.1038/s41379-021-00869-9
doi: 10.1038/s41379-021-00869-9
pubmed: 34247193
pmcid: 8514330
Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002
doi: 10.1016/j.neo.2017.09.002
pubmed: 29091800
pmcid: 5678742
Patel TD, Vazquez A, Dubal PM, Baredes S, Liu JK, Eloy JA (2015) Sinonasal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Int Forum Allergy Rhinol 5(5):448–453. https://doi.org/10.1002/alr.21497
doi: 10.1002/alr.21497
pubmed: 25727332
Perez-Ordoñez B (2018) Neuroendocrine carcinomas of the larynx and head and neck: challenges in classification and grading. Head Neck Pathol 12(1):1–8. https://doi.org/10.1007/s12105-018-0894-6
doi: 10.1007/s12105-018-0894-6
pubmed: 29557536
pmcid: 5873496
Pointer KB, Ko HC, Brower JV, Witek ME, Kimple RJ, Lloyd RV, Baschnagel AM (2017) Small cell carcinoma of the head and neck: an analysis of the National Cancer Database. Oral Oncol 69:92–98. https://doi.org/10.1016/j.oraloncology.2017.04.009
doi: 10.1016/j.oraloncology.2017.04.009
pubmed: 28559027
pmcid: 5553627
Rekhtman N (2022) Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol 35(Suppl 1):36–50. https://doi.org/10.1038/s41379-021-00943-2
doi: 10.1038/s41379-021-00943-2
pubmed: 34663914
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Asa SL (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33(1):115–154. https://doi.org/10.1007/s12022-022-09708-2
doi: 10.1007/s12022-022-09708-2
pubmed: 35294740
Strojan P, Hernandez-Prera JC, Beitler JJ, Eisbruch A, Saba NF, Mendenhall WM, Ferlito A (2019) Small cell and large cell neuroendocrine carcinoma of the larynx: a comparative analysis. Cancer Treat Rev 78:42–51. https://doi.org/10.1016/j.ctrv.2019.08.002
doi: 10.1016/j.ctrv.2019.08.002
pubmed: 31437725
Thompson ED, Stelow EB, Mills SE, Westra WH, Bishop JA (2016) Large cell neuroendocrine carcinoma of the head and neck: a clinicopathologic series of 10 cases with an emphasis on HPV status. Am J Surg Pathol 40(4):471–478. https://doi.org/10.1097/pas.0000000000000580
doi: 10.1097/pas.0000000000000580
pubmed: 26735857
pmcid: 4792746
van der Laan TP, Plaat BE, van der Laan BF, Halmos GB (2015) Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: a meta-analysis of 436 reported cases. Head Neck 37(5):707–715. https://doi.org/10.1002/hed.23666
doi: 10.1002/hed.23666
pubmed: 24596175
van der Laan TP, Iepsma R, Witjes MJ, van der Laan BF, Plaat BE, Halmos GB (2016) Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol 63:1–9. https://doi.org/10.1016/j.oraloncology.2016.10.002
doi: 10.1016/j.oraloncology.2016.10.002
pubmed: 27938993
Yu CX, Yibulayin F, Feng L, Wang M, Lu MM, Luo Y, Wushou A (2020) Clinicopathological characteristics, treatment and prognosis of head & neck small cell carcinoma: a SEER population-based study. BMC Cancer 20(1):1208. https://doi.org/10.1186/s12885-020-07522-9
doi: 10.1186/s12885-020-07522-9
pubmed: 33287756
pmcid: 7722424